A Cardiac PET Program with N-13 Ammonia May be More Practical Than You Think

Partner News | Published: Tuesday, February 7, 2023

---

Cardiac PET MPI has proven to be a powerful clinical diagnostic tool, and N-13 ammonia has been shown to have the highest extraction/retention rates and spatial/contrast resolution of the currently available FDA-approved tracers. However, until recently N-13 ammonia was not practical for use in some settings due to space requirements and inefficient production. Ionetix Corporation has created a solution that makes N-13 ammonia a reliable option for higher throughput physician offices or independent diagnostic testing facilities.

In a recent article in the SNMI Value Initiative November 2022 Newsletter, April Mann, MBA, CNMT, NCT, RT(N), FSNMMI-TS, VP, Clinical Development, Ionetix, demonstrates how their solution and integrated N-13 ammonia manufacturing process allowed for timely dose production and flexibility in protocol selection, resulting in efficient patient throughput as well as physician and patient satisfaction, in their partnership with Centers for Research and Imaging of America (CIRA).

For more, be sure to read April’s full article, Efficient Patient Throughput Performing Cardiac PET Myocardial Perfusion Imaging with N-13 Ammonia in an Outpatient Office Setting: A Customer Experience.

MedAxiom is proud to partner with Ionetix. See how they are partnering with providers to deliver better patient outcomes by visiting their Education Center, featuring useful insights and information through case studies, peer-reviewed white papers, and a featured webinar series on implementing a Cardiac PET Program.

« Back